Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00740610 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT00740610 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 124 participants.
The verdict
NCT00740610, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The overall purpose of this study is to examine the safety, tolerability, pharmacokinetics (how the body processes a drug), and activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by Non-Alcoholic Steatohepatitis (also known as NASH).
Interventions
- DRUG GS-9450
- DRUG GS-9450 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00740610
The ClinicalTrials.gov registry entry for NCT00740610 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GS-9450 is the first listed.
NCT00740610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00740610 about?
NCT00740610 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)". The overall purpose of this study is to examine the safety, tolerability, pharmacokinetics (how the body processes a drug), and activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by Non-Alcoholic Steatohepatitis (also known as NASH).
What is the current status of trial NCT00740610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2008-08. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00740610?
The interventions under investigation include: GS-9450 (DRUG), GS-9450 Placebo (DRUG).
Who is sponsoring clinical trial NCT00740610?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.